Identification of ses-3 and the uses of the same
The invention relates to isolated nucleic acid molecules coding for SES-3 proteins or muted SES-3 proteins, and vectors and transgenic organisms containing such nucleic acid molecules. The invention also relates to uses of such nucleic acid molecules or others which are functionally similar, for producing pharmaceuticals and for producing model organisms. The invention further relates to the corresponding SES-3 proteins and muted SES-3 proteins, and the antibodies induced thereby. Finally, the invention relates to the use of substances which increase the expression of human presenilin, for the treatment of Alzheimer's disease, in addition to said substances themselves and pharmaceutical compositions containing the same.
1 - 31 . (Cancelled).
32 . An isolated nucleic acid molecule that encodes SES-3 or a mutated form of SES-3.
33 . An isolated nucleic acid as described in claim 32 , wherein the mutated form of SES-3 is a protein having at least one of an FAD binding site and an amino oxidase motif.
34 . An isolated nucleic acid as described in claim 32 , wherein the mutated form is a protein having one or more alterations in activity.
35 . An isolated nucleic acid molecule as described in claim 32 , which is DNA, cDNA, genomic DNA, or RNA.
36 . An isolated nucleic acid molecule as described in claim 32 , wherein the SES-3 has an amino acid sequence identical to, or essentially the same as, SEQ ID NO: 1.
37 . An isolated nucleic acid molecule as described in claim 32 , comprising a nucleotide sequence of SEQ ID NO: 2, or a sequence that is complementary thereto.
38 . An isolated nucleic acid molecule, comprising a nucleotide sequence having at least 75% sequence similarity to a nucleotide sequence as described in claim 37 , or a sequence complementary thereto.
39 . An isolated nucleic acid molecule that hybridizes with an isolated nucleic acid molecule as described in claim 37 under conditions of 0.1×SSC at 68 degrees centigrade.
40 . A vector that comprises an isolated nucleic acid molecule or a fragment thereof as described in claim 32 .
41 . A vector as described in claim 40 , which comprises a promoter for expression in a eukaryote cell.
42 . A vector as described in claim 40 , which is in the form of a plasmid, a cosmid, a bacmid, a virus or a bacteriophage.
43 . An SES-3 protein comprising the amino acid sequence of SEQ ID NO: 1, or a fragment thereof.
44 . A mutated SES-3 protein, or a fragment thereof.
45 . An SES-3 protein as described in claim 43 , comprising one or more additions, deletions, or alterations at one or more amino acid positions corresponding to one or more amino acids of SEQ ID NO: 1.
46 . An antibody produced against an SES-3 protein as described in claim 43 .
47 . An antibody as described in claim 46 , wherein the antibody is a monoclonal antibody or a polyclonal antibody.
48 . A transgenic, nonhuman organism that comprises a nucleic acid molecule as described in claim 32 .
49 . A transgenic, nonhuman organism as described in claim 48 , wherein the organism is C. elegans.
50 . A transgenic C. elegans organism as described in claim 49 , which expresses an SES-3 allele that decreases, amplifies or eliminates the activity of SES-3.
51 . A transgenic C. elegans organism as described in claim 50 , which expresses an SES-3 allele that offsets the egg-laying defect phenotype (EgI) in sel-12 C. elegans mutants.
52 . A transgenic C. elegans organism as described in claim 50 , which expresses an SES-3 allele that increases the activity of hop-1 or sel-12.
53 . A transgenic organism that comprises a foreign SES-3 gene homologue.
54 . A transgenic organism as described in claim 53 , wherein the homologue is human gene KIAA0601 or Drosophila melanogaster ALT1.
55 . A method of producing a pharmaceutically active substance useful for treating neurodegenerative disease, comprising expressing an isolated nucleic acid molecule as described in claim 32 , or a functionally similar gene, to produce a gene product and then isolating the gene product.
56 . A method for preparing a transgenic organism for investigating neurodegenerative disease, comprising incorporating an isolated nucleic acid molecule as described in claim 32 into an organism.
57 . A method for discovering substances that alter the activity of SES-3, comprising monitoring SES-3 activity in the presence of a test substance, and identifying or characterizing an effect of the substance on the monitored activity.
58 . The method of claim 57 , wherein the SES-3 activity is monitored in a transgenic organism or transgenic cell.
59 . The method of claim 58 , wherein the transgenic organism is E. elegans.
60 . A method for evaluation of substances that increase the activity of at least one of hop-1 and sel-12 in a transgenic cell or organism containing a nucleic acid molecule as described in claim 1 , comprising monitoring the activity in the presence of a test substance, and identifying or characterizing an effect of the substance on the monitored activity.
61 . The method of claim 29 , wherein the organism is C. elegans.
62 . A method for evaluation of substances that affect the expression of presenilin in a transgenic cell or organism containing a nucleic acid molecule as described in claim 1 , comprising monitoring presenilin expression in the presence of a test substance, and identifying or characterizing an effect of the substance on the monitored expression.
63 . A method for producing a medicament for treating Alzheimer's disease, comprising providing a substance identified by the method of claim 31 , and formulating the substance into a pharmaceutical.
64 . A substance that increases the expression of human presenilin I or presenilin 2, comprising a molecule discovered by the method of claim 62 .
65 . A pharmaceutical composition that comprises a substance as described in claim 64.